(Q37222484)

19 August 2017

1 reference

title

Cervical cancer screening following prophylactic human papillomavirus vaccination (English)

1 reference

19 August 2017

cervix uterine cancer

1 reference

Eduardo L Franco

1

0 references

Jack Cuzick

series ordinal

2

object named as

Jack Cuzick

1 reference

PubMed ID

18642468

19 August 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

19 August 2017

1 reference

19 August 2017

26 Suppl 1

1 reference

19 August 2017

A16-23

1 reference

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

American Cancer Society guideline for the early detection of cervical neoplasia and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Chapter 10: New dimensions in cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Human papillomavirus and Papanicolaou tests to screen for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Could HPV testing become the sole primary cervical screening test?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Management of women who test positive for high-risk types of human papillomavirus: the HART study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Is HPV testing with cytological triage a more logical approach in cervical cancer screening?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.069

10.1016/J.VACCINE.2007.11.069

7 January 2021

Identifiers

DOI

1 reference

release_vfdiyhotgzayli2p7mlzjsfzqm

19 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vfdiyhotgzayli2p7mlzjsfzqm

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

18642468

1 reference

PubMed ID

18642468